Precision BioSciences and TG Therapeutics sign azer-cel licence deal
10 Jan 2024
Gene TherapyCell TherapyLicense out/inPhase 1
Preview
Source: Pharmaceutical Technology
Azercabtagene Zapreleucel will be developed for autoimmune diseases and other non-cancer indications. Credit: Peakstock / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Precision Biosciences and TG Therapeutics have concluded a licensing agreement for the development of the cell therapy azer-cel to treat autoimmune diseases and other non-cancer indications.
The deal includes an upfront payment and potential near-term payments totalling $17.5m in exchange for azer-cel’s global rights.
A $7.5m upfront payment by TG Therapeutics to Precision will comprise both cash and share purchase of the latter’s common stock.
Precision will receive a $2.5m equity investment during 2024.
Achievement of near-term clinical milestones will trigger payment of a further $7.5m for Precision in cash and stock purchases by TG Therapeutics.
Precision will earn $288m in subsequent milestone payments, contingent on clinical, regulatory and commercial goals.
The agreement also entitles Precision to royalties on net product sales.
These financial provisions and available credit are anticipated to extend the cash runway of Precision into the first half of 2026, covering Phase I clinical data readouts for its hepatitis B virus and primary mitochondrial myopathy programmes.
Precision BioSciences president and CEO Michael Amoroso said: “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
“Key factors in our decision to partner with the TG team include their recent development, regulatory and commercial successes in the multiple sclerosis space, which we believe are strong indicators of the commitment and expertise they will bring to the development of azer-cel in autoimmune diseases.
“As TG Therapeutics assumes the development of azer-cel for immunology, Precision will remain focused on capitalising on the utility of ARCUS for gene elimination and gene insertion, beginning with our wholly owned PBGENE-HBV programme for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.